ClinicalTrials.gg
CompletedNCT05186818SEQUOIA-HCMUpdated Mar 3, 2026Results posted

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

A Phase 3 interventional study of Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) and Placebo to match aficamten in Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Cytokinetics. Completed at 114 sites in 14 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Cytokinetics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic — 2 open to participants now, 5 under way, 4 of them phase 3. aficamten · Cardiomyopathy, Hypertrophic.

Enrollment
3rd of 11
282 · median 96
Started
2022
the only one that year
Phase 3
5 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
7 of 11
Cytokinetics

Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, this one is the 3rd largest by enrollment, is the only one that started in 2022, is one of 5 in phase 3, and was the 5th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

2 of the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aficamten

aficamten: first FDA approval 2025 (MYQORZO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) versus placebo in adults with symptomatic hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction.

Read the detailed description

CY 6031 was a Phase 3, randomized, placebo-controlled, double-blind, multi-center trial in participants with symptomatic oHCM. Eligible participants were randomized in a 1:1 ratio to receive aficamten or placebo. Randomization was stratified by use of beta-blockers (yes or no) and cardiopulmonary exercise testing (CPET) exercise modality (treadmill or bicycle). Enrollment limits were applied as follows: participants taking beta-blockers were capped at approximately 70% of total enrollment; participants taking disopyramide were capped at approximately 10% of total enrollment; participants with persistent atrial fibrillation (AF) at screening were capped at approximately 15% of total enrollment; and participants using the bicycle CPET exercise modality were capped at approximately 50% of total enrollment.

Investigational product (IP) was administered orally once daily (QD) with or without food for 24 weeks. During the initial 6 weeks of the treatment period, IP doses were individually titrated at Weeks 2, 4, and 6 based on echocardiography-guided criteria. Dose escalation at Weeks 2, 4, and 6 occurred only if a participant had a Valsalva left ventricular outflow tract gradient (LVOT-G) ≥ 30 mmHg and a biplane left ventricular ejection fraction (LVEF) ≥ 55%. Echocardiograms were performed at each subsequent visit during the trial, and the IP dose was down-titrated if the LVEF was \< 50%. The primary endpoint of peak oxygen uptake (pVO2) was measured by CPET at screening and at the end of treatment (Week 24). A participant's background HCM therapy was individually optimized according to local practice prior to enrollment in the study.

03

Conditions studied

  • Obstructive Hypertrophic Cardiomyopathy (oHCM)

Keywords

  • Obstructive Hypertrophic Cardiomyopathy
  • oHCM
  • CK-3773274
  • CK-274
  • Aficamten
  • SEQUOIA-HCM
  • CY 6031
  • SEQUOIA
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Males and females between 18 and 85 years of age, inclusive, at screening.
  • \<35 kg/m2.
  • Diagnosed with HCM per the following criteria:

    • Has LV hypertrophy and non-dilated LV chamber in the absence of other cardiac disease and
    • Has an end-diastolic LV wall thickness as measured by the echocardiography core laboratory of:

      • ≥15 mm in one or more myocardial segments OR
      • ≥13 mm in one or more wall segments and a known-disease-causing gene mutation or positive family history of HCM
  • Has resting LVOT-G ≥30 mmHg and post-Valsalva LVOT G ≥50 mmHg during screening as determined by the echocardiography core laboratory.
  • ≥60% at screening as determined by the echocardiography core laboratory.
  • (NYHA) Functional Class II or III at screening.
  • ≥10g/dL at screening.
  • Respiratory exchange ratio (RER) ≥1.05 and pVO2 ≤90% predicted on the screening CPET per the core laboratory.
  • Patients on beta-blockers, verapamil, diltiazem, or disopyramide should have been on stable doses for >6 weeks prior to randomization and anticipate remaining on the same medication regimen during the trial. Patients treated with disopyramide must also be concomitantly treated with a beta blocker and/or calcium channel blocker.

Key Exclusion Criteria:

  • Known or suspected infiltrative, genetic or storage disorder causing cardiac hypertrophy that mimics oHCM (eg, Noonan syndrome, Fabry disease, amyloidosis).
  • Significant valvular heart disease (per investigator judgment).

    • Moderate-severe valvular aortic stenosis.
    • Moderate-severe mitral regurgitation not due to systolic anterior motion of the mitral valve.
  • History of LV systolic dysfunction (LVEF \<45%) or stress cardiomyopathy at any time during their clinical course.
  • Inability to exercise on a treadmill or bicycle (eg, orthopedic limitations).
  • Has been treated with septal reduction therapy (surgical myectomy or percutaneous alcohol septal ablation) or has plans for either treatment during the trial period.
  • Documented paroxysmal atrial fibrillation during the screening period.
  • Paroxysmal or permanent atrial fibrillation is only excluded IF:

    • rhythm restoring treatment (eg, direct-current cardioversion, atrial fibrillation ablation procedure, or antiarrhythmic therapy) has been required ≤6 months prior to screening.
    • rate control and anticoagulation have not been achieved for at least 6 months prior to screening.
  • History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to screening.
  • Has received prior treatment with CK-3773274 or mavacamten.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
282 participants (actual)

Study arms

  • Experimental
    Aficamten up to 20 mg

    Participants received 5 mg, 10 mg, 15 mg, or 20 mg of aficamten; dose levels were guided by echocardiography assessments. Treatment was administered for up to 24 weeks.

    Drug: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)

  • Placebo comparator
    Placebo to match aficamten

    Participants received placebo for up to 24 weeks.

    Drug: Placebo to match aficamten

Interventions

  • DrugAficamten (5 mg, 10 mg, 15 mg, and 20 mg)

    Drug page: Aficamten

    Aficamten tablets were administered orally once daily.

    Also known as: CK-3773274

  • DrugPlacebo to match aficamten

    Placebo tablets were administered orally once daily.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in pVO2 at Week 24

    The effect of CK-3773274 on exercise capacity in participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) was determined through changes in peak oxygen uptake (pVO2) after 24 weeks of treatment. pVO2 was measured by cardiopulmonary exercise testing (CPET) on a treadmill or bicycle. A higher pVO2 indicates better cardiorespiratory fitness.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Change From Baseline in KCCQ-CSS at Week 24

    The effect of aficamten on patient health status was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcome designed to assess the physical limitations, symptoms, self-efficacy, social limitation, and quality of life of patients with heart failure symptoms. The KCCQ-Clinical Symptoms Score (KCCQ-CSS) is scored on a scale from 0 to 100, with higher scores indicating better physical functioning and symptoms.

    Time frame: Baseline to Week 24

  2. Change From Baseline in KCCQ-CSS at Week 12

    The effect of aficamten on patient health status was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcome designed to assess the physical limitations, symptoms, self-efficacy, social limitation, and quality of life of patients with heart failure symptoms. The KCCQ-Clinical Symptoms Score (KCCQ-CSS) is scored on a scale from 0 to 100, with higher scores indicating better physical functioning and symptoms.

    Time frame: Baseline to Week 12

  3. Proportion of Participants With ≥1 Class Improvement in New York Heart Association (NYHA) Functional Class From Baseline to Week 24

    The effect of aficamten on NYHA functional classification was evaluated through changes observed from baseline through 24 weeks of treatment.

    Time frame: Baseline to Week 24

  4. Proportion of Participants With ≥1 Class Improvement in NYHA Functional Class From Baseline to Week 12

    The effect of aficamten on NYHA functional classification was evaluated through changes observed from baseline through 12 weeks of treatment.

    Time frame: Baseline to Week 12

  5. Change From Baseline in Valsalva Left Ventricular Outflow Tract Gradient (LVOT-G) at Week 24

    The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 24.

    Time frame: Baseline to Week 24

  6. Change From Baseline in Valsalva LVOT-G at Week 12

    The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 12.

    Time frame: Baseline to Week 12

  7. Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 24

    The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 24.

    Time frame: Baseline to Week 24

  8. Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 12

    The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 12.

    Time frame: Baseline to Week 12

  9. Duration of SRT Eligibility During the 24-week Treatment Period for Participants Who Were SRT Eligible at Baseline

    The effect of aficamten treatment on the duration of septal reduction therapy (SRT) eligibility was evaluated over the 24- week treatment period.

    Time frame: Baseline to Week 24

  10. Change From Baseline to Week 24 in Total Workload During CPET

    Effect of aficamten on intensity of exercise (based on speed, incline, participant weight, etc.) during CPET. Workload is an indication of the energy expended during the exercise test.

    Time frame: Baseline to Week 24

07

Results

Posted Mar 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneAficamten up to 20 mgPlacebo to Match Aficamten
Started142140
Completed137136
Not completed54
Withdrew: Adverse event12
Withdrew: Physician decision01
Withdrew: Protocol violation20
Withdrew: Withdrawal by subject20
Withdrew: Transportation issue due to covid-1901

Outcome measures

PrimaryChange From Baseline in pVO2 at Week 24

The effect of CK-3773274 on exercise capacity in participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) was determined through changes in peak oxygen uptake (pVO2) after 24 weeks of treatment. pVO2 was measured by cardiopulmonary exercise testing (CPET) on a treadmill or bicycle. A higher pVO2 indicates better cardiorespiratory fitness.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · mL/kg/min
Change From Baseline in pVO2 at Week 24
mL/kg/minAficamten up to 20 mgPlacebo to Match Aficamten
Change From Baseline in pVO2 at Week 241.76 ± 0.250.02 ± 0.25
Statistical analysis
  • Aficamten up to 20 mg vs Placebo to Match Aficamten · ANCOVA · p = <0.0001 · Mean difference (final values): 1.74 · 95% CI 1.04 to 2.44
SecondaryChange From Baseline in KCCQ-CSS at Week 24

The effect of aficamten on patient health status was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcome designed to assess the physical limitations, symptoms, self-efficacy, social limitation, and quality of life of patients with heart failure symptoms. The KCCQ-Clinical Symptoms Score (KCCQ-CSS) is scored on a scale from 0 to 100, with higher scores indicating better physical functioning and symptoms.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in KCCQ-CSS at Week 24
score on a scaleAficamten up to 20 mgPlacebo to Match Aficamten
Change From Baseline in KCCQ-CSS at Week 2411.6 ± 1.04.3 ± 1.0
Statistical analysis
  • Aficamten up to 20 mg vs Placebo to Match Aficamten · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 7.3 · 95% CI 4.6 to 10.1
SecondaryChange From Baseline in KCCQ-CSS at Week 12

The effect of aficamten on patient health status was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcome designed to assess the physical limitations, symptoms, self-efficacy, social limitation, and quality of life of patients with heart failure symptoms. The KCCQ-Clinical Symptoms Score (KCCQ-CSS) is scored on a scale from 0 to 100, with higher scores indicating better physical functioning and symptoms.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in KCCQ-CSS at Week 12
score on a scaleAficamten up to 20 mgPlacebo to Match Aficamten
Change From Baseline in KCCQ-CSS at Week 1211.1 ± 0.94.0 ± 0.9
Statistical analysis
  • Aficamten up to 20 mg vs Placebo to Match Aficamten · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 7.0 · 95% CI 4.5 to 9.5
SecondaryProportion of Participants With ≥1 Class Improvement in New York Heart Association (NYHA) Functional Class From Baseline to Week 24

The effect of aficamten on NYHA functional classification was evaluated through changes observed from baseline through 24 weeks of treatment.

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Proportion of Participants With ≥1 Class Improvement in New York Heart Association (NYHA) Functional Class From Baseline to Week 24
ParticipantsAficamten up to 20 mgPlacebo to Match Aficamten
Proportion of Participants With ≥1 Class Improvement in New York Heart Association (NYHA) Functional Class From Baseline to Week 248334
Statistical analysis
  • Aficamten up to 20 mg vs Placebo to Match Aficamten · Cochran-Mantel-Haenszel · p = <0.0001 · Rate difference: 34.2 · 95% CI 23.4 to 45.0
  • Aficamten up to 20 mg vs Placebo to Match Aficamten · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.4 · 95% CI 2.6 to 7.6
SecondaryProportion of Participants With ≥1 Class Improvement in NYHA Functional Class From Baseline to Week 12

The effect of aficamten on NYHA functional classification was evaluated through changes observed from baseline through 12 weeks of treatment.

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Proportion of Participants With ≥1 Class Improvement in NYHA Functional Class From Baseline to Week 12
ParticipantsAficamten up to 20 mgPlacebo to Match Aficamten
Proportion of Participants With ≥1 Class Improvement in NYHA Functional Class From Baseline to Week 126925
Statistical analysis
  • Aficamten up to 20 mg vs Placebo to Match Aficamten · Cochran-Mantel-Haenszel · p = <0.0001 · Rate difference: 30.8 · 95% CI 20.6 to 41.0
  • Aficamten up to 20 mg vs Placebo to Match Aficamten · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.6 · 95% CI 2.6 to 8.4
SecondaryChange From Baseline in Valsalva Left Ventricular Outflow Tract Gradient (LVOT-G) at Week 24

The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 24.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · mmHg
Change From Baseline in Valsalva Left Ventricular Outflow Tract Gradient (LVOT-G) at Week 24
mmHgAficamten up to 20 mgPlacebo to Match Aficamten
Change From Baseline in Valsalva Left Ventricular Outflow Tract Gradient (LVOT-G) at Week 24-48 ± 2.42 ± 2.4
Statistical analysis
  • Aficamten up to 20 mg vs Placebo to Match Aficamten · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -50 · 95% CI -57 to -44
SecondaryChange From Baseline in Valsalva LVOT-G at Week 12

The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 12.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Valsalva LVOT-G at Week 12
mmHgAficamten up to 20 mgPlacebo to Match Aficamten
Change From Baseline in Valsalva LVOT-G at Week 12-46 ± 2.43 ± 2.4
Statistical analysis
  • Aficamten up to 20 mg vs Placebo to Match Aficamten · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -48 · 95% CI -55 to -42
SecondaryProportion of Participants With Valsalva LVOT G <30 mmHg at Week 24

The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 24.

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 24
ParticipantsAficamten up to 20 mgPlacebo to Match Aficamten
Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 24705
Statistical analysis
  • Aficamten up to 20 mg vs Placebo to Match Aficamten · Cochran-Mantel-Haenszel · p = <0.0001 · Rate difference: 45.7 · 95% CI 36.9 to 54.5
  • Aficamten up to 20 mg vs Placebo to Match Aficamten · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 25.5 · 95% CI 10.1 to 88.2
SecondaryProportion of Participants With Valsalva LVOT G <30 mmHg at Week 12

The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 12.

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 12
ParticipantsAficamten up to 20 mgPlacebo to Match Aficamten
Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 12748
Statistical analysis
  • Aficamten up to 20 mg vs Placebo to Match Aficamten · Cochran-Mantel-Haenszel · p = <0.0001 · Rate difference: 46.4 · 95% CI 37.3 to 55.5
  • Aficamten up to 20 mg vs Placebo to Match Aficamten · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 18.0 · 95% CI 7.8 to 44.4
SecondaryDuration of SRT Eligibility During the 24-week Treatment Period for Participants Who Were SRT Eligible at Baseline

The effect of aficamten treatment on the duration of septal reduction therapy (SRT) eligibility was evaluated over the 24- week treatment period.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · days
Duration of SRT Eligibility During the 24-week Treatment Period for Participants Who Were SRT Eligible at Baseline
daysAficamten up to 20 mgPlacebo to Match Aficamten
Duration of SRT Eligibility During the 24-week Treatment Period for Participants Who Were SRT Eligible at Baseline35.3 ± 7.9113.4 ± 8.1
Statistical analysis
  • Aficamten up to 20 mg vs Placebo to Match Aficamten · ANCOVA · p = <0.0001 · Ls mean difference: -78.1 · 95% CI -99.8 to -56.3
SecondaryChange From Baseline to Week 24 in Total Workload During CPET

Effect of aficamten on intensity of exercise (based on speed, incline, participant weight, etc.) during CPET. Workload is an indication of the energy expended during the exercise test.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · watts
Change From Baseline to Week 24 in Total Workload During CPET
wattsAficamten up to 20 mgPlacebo to Match Aficamten
Change From Baseline to Week 24 in Total Workload During CPET13.4 ± 2.11.2 ± 2.1
Statistical analysis
  • Aficamten up to 20 mg vs Placebo to Match Aficamten · ANCOVA · p = <0.0001 · Ls mean difference: 12.2 · 95% CI 6.4 to 18.0

Adverse events

Collected over 28 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aficamten up to 20 mg0/142 (0%)8/142 (5.6%)44/142 (31%)
Placebo to Match Aficamten0/140 (0%)13/140 (9.3%)46/140 (32.9%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventAficamten up to 20 mgPlacebo to Match Aficamten
Hypertrophic cardiomyopathyCongenital, familial and genetic disorders3/1421/140
Acute coronary syndromeCardiac disorders0/1421/140
Acute myocardial infarctionCardiac disorders0/1421/140
Atrial fibrillationCardiac disorders1/1421/140
Cardiac failure congestiveCardiac disorders0/1421/140
Sinoatrial blockCardiac disorders0/1421/140
Ventricular fibrillationCardiac disorders0/1421/140
Upper gastrointestinal haemorrhageGastrointestinal disorders0/1421/140
CellulitisInfections and infestations0/1421/140
PneumoniaInfections and infestations0/1421/140
Most frequent other events
Most frequent other events
EventAficamten up to 20 mgPlacebo to Match Aficamten
Upper respiratory tract infectionInfections and infestations9/14212/140
HeadacheNervous system disorders11/14210/140
HypertensionVascular disorders11/1423/140
PalpitationsCardiac disorders10/1424/140
COVID-19Infections and infestations8/1429/140
DyspnoeaRespiratory, thoracic and mediastinal disorders8/1428/140
Angina pectorisCardiac disorders3/1427/140
FatigueGeneral disorders3/1427/140

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aficamten up to 20 mgPlacebo to Match AficamtenTotal
Median59.0 (18 to 83)60.0 (23 to 84)59.5 (18 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)Aficamten up to 20 mgPlacebo to Match AficamtenTotal
Female5659115
Male8681167
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aficamten up to 20 mgPlacebo to Match AficamtenTotal
American Indian or Alaska Native000
Asian292554
Native Hawaiian or Other Pacific Islander000
Black or African American303
White108115223
More than one race000
Other202
Region of Enrollment
Region of Enrollment(Participants)Aficamten up to 20 mgPlacebo to Match AficamtenTotal
China242246
Czechia011
Denmark437
France9817
Germany8311
Hungary257
Israel459
Italy6612
Netherlands167
Poland61117
Portugal224
Spain171532
United Kingdom10818
United States494594
pVO2 per CPET
pVO2 per CPET(mL/kg/min)Aficamten up to 20 mgPlacebo to Match AficamtenTotal
Mean18.4 ± 4.518.6 ± 4.518.5 ± 4.5
08

Study locations

114 sites
  • Alaska Heart and Vascular Institute
    Anchorage, Alaska 99508, United States
  • UC San Diego Health - Sulpizio Cardiovascular Center
    La Jolla, California 92037, United States
  • Cedars-Sinai Medical Center - Smidt Heart Institute Clinic
    Los Angeles, California 90048, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • Stanford University Hospital
    Stanford, California 94305, United States
  • Yale School of Medicine
    New Haven, Connecticut 06511, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06519, United States
  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
  • Holy Cross Hospital / Cardiology Associates
    Fort Lauderdale, Florida 33308, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • Emory Clinic
    Atlanta, Georgia 30322, United States
  • Piedmont Fayette Hospital
    Fayetteville, Georgia 30214, United States
  • Northwestern University
    Chicago, Illinois 60614, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • MedStar Medical Group Cardiology at Union Memorial
    Baltimore, Maryland 21218, United States
  • Medstar Franklin Square Medical Center
    Baltimore, Maryland 21237, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Lahey Hospital & Medical Center
    Burlington, Massachusetts 01805, United States
  • Michigan Medicine
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Medical Center
    Detroit, Michigan 48202, United States
  • Spectrum Health Medical Group Cardiovascular Medicine
    Grand Rapids, Michigan 49525, United States
  • M Health Fairview University of Minnesota Medical Center - East Bank
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Columbia University Medical Center/NY Presbyterian Hospital
    New York, New York 10032, United States
  • Westchester Medical Center
    Valhalla, New York 10595, United States
  • Sanger Heart and Vascular Institute
    Charlotte, North Carolina 10595, United States
  • Sanger Heart and Vascular Institute - HCM Clinic
    Charlotte, North Carolina 28204, United States
  • Duke Health Center Arringdon
    Morrisville, North Carolina 27560, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Ascension St. John Clinical Research Institute
    Tulsa, Oklahoma 74104, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Hospital of the University of Pennsylvania (University of Pennsylvania School of Medicine)
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Presbyterian
    Pittsburgh, Pennsylvania 15213, United States
  • Stern Cardiovascular Foundation, Inc
    Germantown, Tennessee 38138, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • The University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • University of Utah Hospital
    Salt Lake City, Utah 84132, United States
  • University of Virginia Health System University Hospital
    Charlottesville, Virginia 22908, United States
  • University of Washington Medical
    Seattle, Washington 98195, United States
  • Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
  • Beijing Chao-Yang Hospital, Capital Medical University
    Beijing, Beijing Municipality 100020, China
  • Beijing Anzhen Hospital
    Beijing, Beijing Municipality 100029, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality 10019, China
  • Nanfang Hospital Southern Medical University
    Guanzhou, Guangdong 516006, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450018, China
  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Xiangya Hospital of the Central South University
    Changsha, Hunan 410008, China
  • The First Hospital of Jinlin University
    Changchun, Jinlin 130031, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi’an, Shanxi 710061, China
  • Charles University
    Prague, 128 08, Czechia
  • Interni klinika kardiologie a angiologie
    Prague, 12808, Czechia
  • Aalborg University Hospital, Department of Cardiology
    Aalborg, 9100, Denmark
  • Department of Cardiology Aarhus University Hospital
    Aarhus, 8200, Denmark
  • Hjertecentret (The Heart Center)
    Copenhagen, 2100, Denmark
  • Copenhagen University Hospital
    Copenhagen, 2400, Denmark
  • Hopital Universitaire de Rangueil (CHU de Toulouse) Service de Cardiologie
    Toulouse, Cedex 31059, France
  • CHU de Marseille - Hopital de la Timone Service de cardiologie
    Marseille, 13005, France
  • CHU de Nantes
    Nantes, 44093, France
  • Hopital Lariboisiere, Service de Cardiologie
    Paris, 75010, France
  • Hôpital Européen Georges Pompidou
    Paris, 75015, France
  • CHU Pitie-Salpetriere, Centre de reference maladies cardiaques hereditaires ou rares
    Paris, France
  • CHU de Bordeaux Hopital Cardiologique Haut-Leveque
    Pessac, 33600, France
  • CHU du Haut Lveque Cardiologie
    Pessac, 33604, France
  • Kerckhoff-Klinik GmbH Abteilung Administration Forschung und Lehre
    Bad Nauheim, 61231, Germany
  • Charite-Universitaetsmedizin Berlin Campus Virchow-Klinikum (CVK) Medizinische Klinik mit Schwerpunkt Kardiologie
    Berlin, 13353, Germany
  • Universitaetsklinikum Essen Westdeutsches Herz-Gefaesszentrum
    Essen, 45147, Germany
  • Klinikumder Georg-August-Universitaet
    Göttingen, 37075, Germany
  • Universitaetsmedizin Goettingen
    Göttingen, 37075, Germany
  • Universitaetsklinikum Heidelberg
    Heidelberg, Germany
  • Universitaetsklinikum Jena Klinik fuer Innere Medizin 1
    Jena, 07747, Germany
  • Unniversitaetsklinikum Magdeburg Klinik fur Kardiologie und Anglologie
    Magdeburg, 39120, Germany
  • Universitätsklinikum Würzburg
    Würzburg, Germany
  • Semmelweis Egyetem Varosmajori Sziv es Ergyogyasazati Klinika
    Budapest, Hungary
  • The Olga & Lev Leviev Heart Center The Chaim Sheba Medical Center
    Ramat Gan, Tel Hasomer 5265601, Israel
  • The Barzilai University Medical Center
    Ashkelon, 78100, Israel
  • The Barzilai University Medical Center
    Ashkelon, 7830604, Israel
  • Hadassah Medical Center- Ein Kerem
    Jerusalem, 9112001, Israel
  • Kaplan Medical Center
    Rehovot, 76100, Israel
  • Ziv Medical Center
    Safed, 13100, Israel
  • UOC Cardiologica Azienda Ospedaliera Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Azienda Ospedaliero Universitaria Careggi Dipartimento Cardiotoracovascolare - Cardiomiopatie Unit
    Florence, 50134, Italy
  • Fondazione toscana Gabriele Monesterio per la ricarca medica Dipartimento Cardiotoracico UOC Cardiologia e Medicina Cardiovasculare Ospedale San Cataldo
    Pisa, 56124, Italy
  • Dipartimento di Medicina Clinica e Molecolare Universita Sapienza di Roma Unita di Terapia Intensiva Cardiologica Azienda Ospedaliero Universitaria Sant'Andrea
    Roma, 1035-39, Italy
  • Amsterdam UMC, location AMC
    Amsterdam, 1105, Netherlands
  • University Hospital Maastricht
    Maastricht, 6229HX, Netherlands
  • Erasmus Medical Center
    Rotterdam, 3015, Netherlands
  • Narodowy Instytut Kardiologii Stefana Kardynała Wyszynskiego- Panstwowy Instytut Badawczy
    Warsaw, Masovian Voivodeship 04-628, Poland
  • Kardio Brynow S.C
    Katowice, Poland
  • Krakowskie Centrum
    Krakow, Poland
  • Centro Hospitalar Do Baixo Vouga, EPE AV ARTUR RAVARA
    Aveiro, 3814-501, Portugal
  • Hospital da Luz
    Lisbon, 1500-650, Portugal
  • Complejo Hospitalario Universitario
    A Coruña, La Coruna 15006, Spain

Showing the first 100 of 114 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kaski JP, Kantor PF, Nakano SJ, Olivotto I, Russell MW, Godown J, Chiu M, German P, Heitner SB, Jacoby DL, Kupfer S, Lutz J, Maharao N, Malik FI, Melloni C, Nieto Morales PF, Simkins T, Wei J, Ho CY; CEDAR-HCM Investigators. Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM. Circ Heart Fail. 2026 Feb;19(2):e013418. doi: 10.1161/CIRCHEARTFAILURE.125.013418. Epub 2025 Dec 5. PubMed 41347307 ↗
  • Campain J, Griskowitz C, Newlands C, Claggett BL, Kulac IJ, McGinnis S, Giverts I, Moreno F, Minasian A, Prasad C, Rupert L, Landsteiner I, Iskenderian N, Coats CJ, Lee MMY, Maron MS, Owens AT, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Malhotra R, Lewis GD. Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. Circulation. 2025 Oct 7;152(14):990-1002. doi: 10.1161/CIRCULATIONAHA.124.073585. Epub 2025 Sep 5. PubMed 40910168 ↗
  • Maron MS, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, Dungen HD, Garcia-Pavia P, Hagege AA, Januzzi JL, Kulac I, Lee MMY, Lewis GD, Ma CS, Michels M, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins HC, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Olivotto I; SEQUOIA-HCM Investigators. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Coll Cardiol. 2024 Nov 5;84(19):1821-1831. doi: 10.1016/j.jacc.2024.09.003. Epub 2024 Sep 30. PubMed 39352339 ↗
  • Lee MMY, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Claggett BL, Coats CJ, Gimeno JR, Kulac IJ, Landsteiner I, Ma C, Maron MS, Olivotto I, Owens AT, Solomon SD, Veselka J, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Lewis GD; SEQUOIA-HCM Investigators. Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial. JAMA Cardiol. 2024 Nov 1;9(11):990-1000. doi: 10.1001/jamacardio.2024.2781. PubMed 39230885 ↗
  • Sherrod CF 4th, Saberi S, Nassif ME, Claggett BL, Coats CJ, Garcia-Pavia P, Januzzi JL, Lewis GD, Ma C, Maron MS, Miao ZM, Olivotto I, Veselka J, Butzner M, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Spertus JA. Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Coll Cardiol. 2024 Nov 5;84(19):1773-1785. doi: 10.1016/j.jacc.2024.08.014. Epub 2024 Sep 1. PubMed 39217569 ↗
  • Masri A, Cardoso RN, Abraham TP, Claggett BL, Coats CJ, Hegde SM, Kulac IJ, Lee MMY, Maron MS, Merkely B, Michels M, Olivotto I, Oreziak A, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Solomon SD, Wohltman A, Kwong RY, Kramer CM; SEQUOIA-HCM Investigators. Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy. J Am Coll Cardiol. 2024 Nov 5;84(19):1806-1817. doi: 10.1016/j.jacc.2024.08.015. Epub 2024 Sep 1. PubMed 39217563 ↗
  • Hegde SM, Claggett BL, Wang X, Jering K, Prasad N, Roshanali F, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Cardim N, Coats CJ, Kramer CM, Maron MS, Michels M, Olivotto I, Saberi S, Jacoby DL, Heitner SB, Kupfer S, Meng L, Wohltman A, Malik FI, Solomon SD; SEQUOIA-HCM Investigators. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2024 Nov 5;84(19):1789-1802. doi: 10.1016/j.jacc.2024.08.002. Epub 2024 Sep 1. PubMed 39217556 ↗
  • Coats CJ, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Dungen HD, Garcia-Pavia P, Hagege AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Maron MS, Miao ZM, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, German P, Heitner SB, Kupfer S, Lutz JD, Malik FI, Meng L, Wohltman A, Abraham TP; SEQUOIA-HCM Investigators *. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Heart Assoc. 2024 Aug 6;13(15):e035993. doi: 10.1161/JAHA.124.035993. Epub 2024 Jul 26. PubMed 39056349 ↗
  • Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, Dungen HD, Garcia-Pavia P, Hagege AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham TP; SEQUOIA-HCM Investigators. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2024 May 30;390(20):1849-1861. doi: 10.1056/NEJMoa2401424. Epub 2024 May 13. PubMed 38739079 ↗
  • Coats CJ, Maron MS, Abraham TP, Olivotto I, Lee MMY, Arad M, Cardim N, Ma CS, Choudhury L, Dungen HD, Garcia-Pavia P, Hagege AA, Lewis GD, Michels M, Oreziak A, Owens AT, Tfelt-Hansen J, Veselka J, Watkins HC, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Wohltman A, Masri A; SEQUOIA-HCM Investigators. Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design. JACC Heart Fail. 2024 Jan;12(1):199-215. doi: 10.1016/j.jchf.2023.10.004. Epub 2023 Nov 29. PubMed 38032573 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Nov 2023, 21 months.

Results were first posted in Mar 2026, 2 years 3 months after primary completion. A results delay was requested in Nov 2024.

Of 15 phase 3 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 21 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2021
First posted
Jan 11, 2022
StartActual
Feb 1, 2022
Primary completionActual
Nov 10, 2023
CompletionActual
Dec 18, 2023
Results delay requested
Nov 27, 2024
Results first posted
Mar 3, 2026
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05186818
Lead sponsor
Cytokinetics
Collaborators
Corxel Pharmaceuticals
Responsible party
Sponsor
First posted
Jan 11, 2022
Start date
Feb 1, 2022
Primary completion
Nov 10, 2023
Completion
Dec 18, 2023
Results posted
Mar 3, 2026
Last update
Mar 3, 2026

Study contacts

Cytokinetics MD
study director · Cytokinetics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aficamten

Start the discussion